about
Cancer classification using the Immunoscore: a worldwide task forceSupporting the advancement of science: open access publishing and the role of mandatesImmunotherapy in non-small cell lung cancer: the clinical impact of immune response and targetingCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsCell injury, retrodifferentiation and the cancer treatment paradoxBiomarkers for glioma immunotherapy: the next generationTargeting the tumor microenvironment: JAK-STAT3 signalingTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyCOTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.Managing Multi-center Flow Cytometry Data for Immune Monitoring.Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).Preamble to the 2015 SITC immunotherapy biomarkers taskforceThe novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cellsIntra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.Effects of oxygen on the antigenic landscape of prostate cancer cells.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.The effects of storage temperature on PBMC gene expression.A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceAcute inflammation induces immunomodulatory effects on myeloid cells associated with anti-tumor responses in a tumor mouse model.Multiple vaccinations: friend or foe.Cytokine-induced killer cells promote antitumor immunityDesign and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response.Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapiesTARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.Systems level immune response analysis and personalized medicine.Cancer vaccines: identification of biomarkers predictive of clinical efficacyApplications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome.
P2860
Q21245495-8F769BE6-1D73-463D-93B6-8145A13C7A47Q24288945-F8AB903C-E9D0-44B1-ACD0-6956A66E147CQ26738673-A674A8BC-ABE8-472E-8BA2-F13B1164222CQ26745516-73F35EF6-EC7B-41E5-B29E-00BDC4DDCE1AQ26765115-11982328-7B0F-4B7D-B6AA-563CB2A720E2Q26783201-360CECF3-775A-4AE8-ACF9-F87093236DDCQ26825496-B1C4BA4B-8F91-4F20-A5A6-A37D94853A38Q26825658-3FFC292A-FD8E-4A35-AC3F-6F7C8303DEEDQ27026489-C6D9A9F6-55A2-45E0-9925-2773FA8873F8Q28084489-CD97A34C-5153-49B7-9B2C-FAFE11FBFB9BQ30367429-CCBEB916-BAFE-4B30-BD5F-96C4A01741EEQ30974350-9D292347-85E6-4C51-8E36-AB4C40A61948Q33564510-1E93F1DC-5BC2-4CED-818A-4449431C9D56Q33700800-87468DEB-C1B0-468C-AFBA-286B2F31137AQ33859814-7605AFCF-07E8-4198-A96D-E2DBD761A14BQ34119366-2DEC7445-105F-4DBD-BE9A-897747A891D5Q34292741-9BD88E9F-52ED-40BA-82AD-97E07D4E78A7Q34331673-6947FCA4-52A9-4BAD-9AFA-76449B374893Q34608796-E58ACBC2-C0DB-458D-9F5D-33AD7A6E09A5Q35212166-C30341F5-0CEF-43A3-84E8-203F9993EB45Q35495820-2CA64651-09B9-4DDB-BF97-5A136A415A01Q35517613-99970D7F-D932-43E6-9B54-F24A42C1D7DFQ35546878-0B256E57-859E-4274-96DC-7D34C10781ACQ35845496-FE1370E1-B1F7-4019-B3AC-B00D72C6AE2EQ35925674-753CBFB1-8C93-4C1A-9C01-ED66763FA99EQ35958116-196B6F28-B660-490E-98CC-0CA23D49FD82Q36062047-EC73BA39-6D71-4058-9C6C-8427A90F9A2FQ36547213-0FE5ADFB-BA5E-43DF-8540-72B5D482A50BQ36555546-EBDF74E4-DF13-4730-8984-5FB622943D5FQ36620354-0EEDD104-C4F8-4CA6-981C-58BBA1DDA6A4Q36734688-EF17431E-CA12-45BB-8979-83F6B7908AF2Q36741617-93CF1557-5711-4DE5-9548-7FFD35F63253Q36777133-6E513A4E-AAD8-49A0-9F3E-9DEBCD9FE28BQ36881910-C20F9B56-AC4A-468C-9A4C-6AD178A3145BQ37047061-4478BD60-E5CC-4D8B-BFFD-A5FD44AD6446Q37224581-AA533F4D-3DC5-4870-99F1-F6420F40D156Q38088013-08EA59FE-77DB-4F55-94A9-B42D485DD79CQ38096025-C81B541E-11D0-4E78-94C2-02F5895BB440Q38096820-627E05E8-0F7C-4387-8A86-C9CEB76F389FQ38127467-202727DB-74B7-47BA-8A0E-EDE2576B6F95
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Defining the critical hurdles in cancer immunotherapy.
@ast
Defining the critical hurdles in cancer immunotherapy.
@en
type
label
Defining the critical hurdles in cancer immunotherapy.
@ast
Defining the critical hurdles in cancer immunotherapy.
@en
prefLabel
Defining the critical hurdles in cancer immunotherapy.
@ast
Defining the critical hurdles in cancer immunotherapy.
@en
P2093
P2860
P50
P356
P1476
Defining the critical hurdles in cancer immunotherapy.
@en
P2093
A Raja Choudhury
Alfred E Chang
Antoni Ribas
Barbara Seliger
Beatrix Kotlan
Bernard A Fox
Carl H June
Cedrik M Britten
Christoph Huber
P2860
P2888
P356
10.1186/1479-5876-9-214
P50
P577
2011-12-14T00:00:00Z
P5875
P6179
1006168982